Related Experiment Videos
Defining optimal therapy for the thrombolysis-ineligible patient
1Division of Cardiology, Hahnemann University Hospital, Philadelphia, Pennsylvania 19102, USA. marc.cohen@tenethealth.com
Clinical Cardiology
|November 14, 2002
Summary
Enoxaparin and tirofiban show excellent efficacy and safety for patients with ST-elevation myocardial infarction (STEMI) ineligible for reperfusion therapy. This combination offers a vital treatment option for acute coronary syndrome (ACS) patients who cannot undergo standard reperfusion procedures.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Not all acute coronary syndrome (ACS) patients can receive reperfusion therapy due to late presentation or bleeding risks.
- Effective alternative treatments are crucial for patients with acute ST-elevation myocardial infarction (STEMI) who are ineligible for reperfusion.
- Low-molecular-weight heparin, specifically enoxaparin, has demonstrated superiority over unfractionated heparin in thrombolytic therapy adjuncts.
Purpose of the Study:
- To evaluate the efficacy and safety of enoxaparin in combination with tirofiban.
- To assess this combination therapy in STEMI patients ineligible for reperfusion therapy.
Main Methods:
- A clinical trial was conducted to assess enoxaparin plus tirofiban in STEMI patients.
- Blinded data from the entire patient cohort was analyzed.
Main Results:
- The combination therapy demonstrated excellent efficacy in the studied patient cohort.
- The treatment regimen also showed an excellent safety profile.
Conclusions:
- Enoxaparin combined with tirofiban presents a promising therapeutic option for STEMI patients unsuitable for reperfusion.
- This approach addresses a critical unmet need in managing specific acute coronary syndrome populations.